DOCS vs TEM Stock Comparison: AI Score, Valuation, Performance and Upside
Doximity is a highly profitable, capital-light digital network monetizing physician engagement, while Tempus AI is a faster-growing, still-maturing precision medicine data and diagnostics company investing heavily to scale its AI platform. The comparison generally weighs Doximity's proven profitability against Tempus's higher-growth, higher-risk AI-driven healthcare data opportunity.
This comparison is best used to weigh a proven, highly profitable physician network platform against an earlier-stage, faster-growing AI-driven precision medicine company still working toward consistent profitability.
DOCS holds the edge across 3 of 5 key metrics in this comparison. TEM has delivered stronger 1-year price return (-16.89% vs -60.69%), though DOCS has the better forward P/E setup (17.24x vs -4148.03x for TEM). On fundamentals, TEM is growing revenue faster (21.60%), while DOCS maintains the higher operating margin (21.54%) — a classic growth-versus-profitability split. Analyst consensus implies meaningfully more upside for DOCS (+11.49%) than for TEM (+0.49%).
- Want exposure to a highly profitable, capital-light healthcare technology platform
- Value consistent free cash flow generation
- Believe physician engagement and pharma marketing spend will keep growing
- Prefer lower business-model risk within healthcare technology
- Want higher-growth exposure to AI-driven precision medicine and genomics
- Are comfortable with a company still working toward sustained profitability
- Believe proprietary clinical data assets will create a durable competitive moat
- Accept reimbursement and regulatory risk typical of diagnostics businesses
| Metric | DOCS | TEM |
|---|---|---|
| AI score | 23.4 | 31.7 |
| AI rank | #3584 | #2097 |
| Latest close | $26.71 | $63.05 |
| 1M return | +27.74% | +43.72% |
| 6M return | +8.89% | +18.40% |
| 1Y return | -60.69% | -16.89% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | DOCS | TEM |
|---|---|---|
| 1Y ago | $3.99K (-60.1%) started 2025-09-02 | $8.05K (-19.5%) started 2025-09-02 |
| 5Y ago | $2.9K (-71.0%) started 2021-08-31 | $15.66K (+56.6%) started 2024-06-14 |
| 10Y ago | $5.04K (-49.6%) started 2021-06-24 | $15.66K (+56.6%) started 2024-06-14 |
Hypothetical — past performance does not guarantee future results.
| Metric | DOCS | TEM |
|---|---|---|
| Market cap | $4.76B | $11.38B |
| Trailing P/E | 31.80 | N/A |
| Forward P/E | 17.24 | -4148.03 |
| Price/Sales | 7.26 | 7.94 |
| EV/Revenue | 6.23 | 8.51 |
| Analyst target | $29.78 | $63.36 |
| Target upside | +11.49% | +0.49% |
| Metric | DOCS | TEM |
|---|---|---|
| Revenue growth | 7.30% | 21.60% |
| Earnings growth | -51.90% | N/A |
| EPS growth | -51.90% | N/A |
| FCF margin | +36.56% | -6.53% |
| Operating margin | 21.54% | -20.11% |
| Profit margin | 25.48% | -17.77% |
| ROIC proxy | 17.21% | -67.44% |
| Return on equity | 17.21% | -67.44% |
| Dividend yield | 0.00% | 0.00% |
| Beta | 1.21 | 3.58 |
| Debt/equity | 1.06 | 324.58 |
| Current ratio | 6.08 | 3.30 |
| Quick ratio | 5.80 | 3.01 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | DOCS | TEM |
|---|---|---|---|
| 1Y | Growth | -60.13% | -19.52% |
| CAGR | -60.36% | -19.63% | |
| Sharpe ratio | -1.22 | -0.01 | |
| Max drawdown | 76.03% | 59.76% | |
| Max daily drop | 23.00% | 12.36% | |
| Max wkly drop | 30.81% | 20.36% | |
| 5Y | Growth | -70.97% | +56.65% |
| CAGR | -21.92% | +22.49% | |
| Sharpe ratio | -0.12 | 0.64 | |
| Max drawdown | 82.35% | 59.76% | |
| Max daily drop | 23.00% | 19.23% | |
| Max wkly drop | 32.63% | 37.12% | |
| 10Y | Growth | -49.60% | +56.65% |
| CAGR | -12.38% | +22.49% | |
| Sharpe ratio | 0.08 | 0.64 | |
| Max drawdown | 82.35% | 59.76% | |
| Max daily drop | 23.00% | 19.23% | |
| Max wkly drop | 32.63% | 37.12% |
| Category | DOCS | TEM |
|---|---|---|
| Company | Doximity | Tempus AI |
| Sector | Healthcare Technology | Healthcare Technology |
| Industry | N/A | N/A |
| Core business | Doximity operates a digital platform and professional network for physicians, monetizing through pharmaceutical marketing, hiring, and workflow tools sold to healthcare organizations. | Tempus AI provides AI-powered precision medicine tools, combining genomic sequencing, clinical data, and machine learning to help oncologists and other clinicians personalize treatment decisions. |
| Investor focus | Investors track Doximity's physician user engagement, pharmaceutical marketing client spending, and its high-margin, capital-light profitability profile. | Investors track Tempus's revenue growth from diagnostic testing and data licensing, its path to profitability, and adoption of its AI-driven clinical decision tools by health systems and pharma partners. |
- Dominant physician network with high engagement among U.S. doctors
- High gross margins and consistent free cash flow generation
- Diversified revenue across marketing, hiring, and workflow products
- Large proprietary clinical and molecular dataset supporting AI model development
- Fast-growing testing volume and expanding pharma data licensing partnerships
- Positioned at the intersection of genomics, AI, and precision oncology
- Revenue concentration in pharmaceutical and healthcare system marketing budgets
- Growth increasingly depends on expanding average revenue per client
- Competitive pressure from other digital health engagement platforms
- Still working toward sustained GAAP profitability
- Reimbursement and regulatory risk typical of diagnostic testing businesses
- Valuation reflects significant expectations for continued high growth
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.